|
Taiwan Academic Institutional Repository >
Browse by Author
|
"hollebecque a"
Showing items 1-11 of 11 (1 Page(s) Totally) 1 View [10|25|50] records per page
國家衛生研究院 |
2023-01-19 |
Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma
|
Goyal, L; Meric-Bernstam, F; Hollebecque, A; Valle, JW; Morizane, C; Karasic, TB; Abrams, TA; Furuse, J; Kelley, RK; Cassier, PA; Klümpen, HJ; Chang, HM; Chen, LT; Tabernero, J; Oh, DY; Mahipal, A; Moehler, M; Mitchell, EP; Komatsu, Y; Masuda, K; Ahn, D; Epstein, RS; Halim, AB; Fu, Y; Salimi, T; Wacheck, V; He, Y; Liu, M; Benhadji, KA; Bridgewater, JA |
臺大學術典藏 |
2022-09-15T01:08:45Z |
Safety and Antitumor Activity of a-PD-L1 Antibody as Monotherapy or in Combination witha-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors
|
Hollebecque A.; Chung H.C.; Miguel M.J.D.; Italiano A.; MacHiels J.-P.; Chia-Chi Lin; Dhani N.C.; Peeters M.; Moreno V.; Su W.-C.; Chow K.H.; Galvao V.R.; Carlse M.; Yu D.; Szpurka A.M.; Zhao Y.; Schmidt S.L.; Gandhi L.; Xu X.; Bang Y.-J. |
臺大學術典藏 |
2022-08-19T00:20:33Z |
Pembrolizumab for the treatment of programmed death�Vligand 1?positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYnote-028 study
|
?lez E.; Tamura K.; Gould M.; Yang P.; Stein K.; Piha-Paul S.A.; Mehnert J.M.; Bergsland E.; O��Neil B.H.; Santoro A.; Schellens J.H.M.; Cohen R.B.; Doi T.; Ott P.A.; Pishvaian M.J.; Puzanov I.; Aung K.L.; CHIUN HSU; Le Tourneau C.; Hollebecque A. |
臺大學術典藏 |
2022-06-10T06:10:56Z |
First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma
|
Kim R.D.; Sarker D.; Meyer T.; Yau T.; Macarulla T.; Park J.-W.; Choo S.P.; Hollebecque A.; Sung M.W.; Lim H.-Y.; Mazzaferro V.; Trojan J.; Zhu A.X.; Yoon J.-H.; Sharma S.; ZHONG-ZHE LIN; Chan S.L.; Faivre S.; Feun L.G.; Yen C.-J.; Dufour J.-F.; Palmer D.H.; Llovet J.M.; Manoogian M.; Tugnait M.; Stransky N.; Hagel M.; Kohl N.E.; Lengauer C.; Sherwin C.A.; Schmidt-Kittler O.; Hoeflich K.P.; Shi H.; Wolf B.B.; Kang Y.-K. |
國家衛生研究院 |
2022-06 |
Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements
|
Goyal, L;Meric-Bernstam, F;Hollebecque, A;Morizane, C;Valle, JW;Karasic, TB;Abrams, TA;Kelley, RK;Cassier, PA;Furuse, J;Klumpen, HJ;Chang, HM;Chen, LT;Komatsu, Y;Masuda, K;Ahn, DH;Li, K;Benhadji, KA;Wacheck, V;Bridgewater, JA |
國家衛生研究院 |
2021-09 |
Primary results of phase 2 FOENIX-CCA2: the irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements
|
Mohler, M;Goyal, L;Meric-Bernstam, F;Hollebecque, A;Morizane, C;Valle, JW;Karasic, TB;Abrams, TA;Kelley, RK;Cassier, P;Furuse, J;Klumpen, HJ;Chang, HM;Chen, LT;Komatsu, Y;Masuda, K;Ahn, D;He, Y;Soni, N;Benhadji, KA;Bridgewater, JA |
臺大學術典藏 |
2021-08-11T03:46:35Z |
First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma
|
Kim R.D.; Sarker D.; Meyer T.; Yau T.; Macarulla T.; Park J.-W.; Choo S.P.; Hollebecque A.; Sung M.W.; Lim H.-Y.; Mazzaferro V.; Trojan J.; Zhu A.X.; Yoon J.-H.; Sharma S.; ZHONG-ZHE LIN; Chan S.L.; Faivre S.; Feun L.G.; Yen C.-J.; Dufour J.-F.; Palmer D.H.; Llovet J.M.; Manoogian M.; Tugnait M.; Stransky N.; Hagel M.; Kohl N.E.; Lengauer C.; Sherwin C.A.; Schmidt-Kittler O.; Hoeflich K.P.; Shi H.; Wolf B.B.; Kang Y.-K. |
國家衛生研究院 |
2021-07 |
Primary results of phase 2 FOENIX-CCA2: The irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements
|
Goyal, L;Meric-Bernstam, F;Hollebecque, A;Morizane, C;Valle, JW;Karasic, TB;Abrams, TA;Kelley, RK;Cassier, P;Furuse, J;Klumpen, HJ;Chang, HM;Chen, LT;Komatsu, Y;Masuda, K;Ahn, D;He, YH;Soni, N;Benhadji, KA;Bridgewater, JA |
臺大學術典藏 |
2021-02-18T01:45:22Z |
Pembrolizumab for the treatment of programmed death�Vligand 1?positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study
|
Mehnert J.M.;Bergsland E.;O??Neil B.H.;Santoro A.;Schellens J.H.M.;Cohen R.B.;Doi T.;Ott P.A.;Pishvaian M.J.;Puzanov I.;Aung K.L.;Chiun Hsu;Le Tourneau C.;Hollebecque A.;?Lez E.;Tamura K.;Gould M.;Yang P.;Stein K.;Piha-Paul S.A.; Mehnert J.M.; Bergsland E.; O��Neil B.H.; Santoro A.; Schellens J.H.M.; Cohen R.B.; Doi T.; Ott P.A.; Pishvaian M.J.; Puzanov I.; Aung K.L.; Chiun Hsu; Le Tourneau C.; Hollebecque A.; ?lez E.; Tamura K.; Gould M.; Yang P.; Stein K.; Piha-Paul S.A. |
國立成功大學 |
2021 |
Safety and Antitumor Activity of a-PD-L1 Antibody as Monotherapy or in Combination witha-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors
|
Hollebecque, A.;Chung, H.C.;Miguel, Miguel M.J.D.;Italiano, A.;MacHiels, J.-P.;Lin, C.-C.;Dhani, N.C.;Peeters, M.;Moreno, V.;Su, W.-C.;Chow, K.H.;Galvao, V.R.;Carlse, M.;Yu, D.;Szpurka, A.M.;Zhao, Y.;Schmidt, Schmidt S.L.;Gandhi, L.;Xu, Xu X.;Bang, Y.-J. |
國立成功大學 |
2019 |
First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma
|
Kim, R.D.;Sarker, D.;Meyer, T.;Yau, T.;Macarulla, T.;Park, J.-W.;Choo, S.P.;Hollebecque, A.;Sung, M.W.;Lim, H.-Y.;Mazzaferro, V.;Trojan, J.;Zhu, A.X.;Yoon, J.-H.;Sharma, Sharma S.;Lin, Z.-Z.;Chan, S.L.;Faivre, S.;Feun, L.G.;Yen, C.-J.;Dufour, J.-F.;Palmer, D.H.;Llovet, J.M.;Manoogian, Manoogian M.;Tugnait, M.;Stransky, N.;Hagel, M.;Kohl, N.E.;Lengauer, C.;Sherwin, C.A.;Schmidt-Kittler, O.;Hoeflich, K.P.;Shi, H.;Wolf, B.B.;Kang, Y.-K. |
Showing items 1-11 of 11 (1 Page(s) Totally) 1 View [10|25|50] records per page
|